Difference between revisions of "Aminoglutethimide (Cytadren)"
m (Text replacement - "[[File:" to "[[:File:") |
m (Text replacement - "http://chemocare.com/chemotherapy" to "https://chemocare.com/chemotherapy") |
||
| Line 11: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://chemocare.com/chemotherapy/drug-info/aminoglutethimide.aspx Aminoglutethimide (Cytadren) patient drug information (Chemocare)]<ref>[https://chemocare.com/chemotherapy/drug-info/aminoglutethimide.aspx Aminoglutethimide (Cytadren) patient drug information (Chemocare)]</ref> |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 21:41, 16 December 2021
General information
Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
This medication does not have a specific cancer indication; it is indicated for Cushing Syndrome.
- 10/29/1980: Initial approval
Also known as
- Brand names: Aminoblastin, Cytadren, Elipten, Orimentin, Orimeten, Orimetene, Rodazol